Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Simmerafil in Erectile Dysfunction
NCT06301854Phase 3Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of TPN171H in erectile dysfunction (ED), sponsored by Vigonvita Life Sciences. Primary endpoint: Incidence of adverse events (AE) and adverse drug reactions (ADRs) at 12 months. Started Apr 2024; status: completed.
02
Drugs
TPN171H
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT06301854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301854.